

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

NCI-H82

RRID:CVCL_1591

Type: Cell Line

Proper Citation

RRID:CVCL_1591

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1591

Proper Citation: RRID:CVCL_1591

Description: Cell line NCI-H82 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung small cell carcinoma

Defining Citation: [PMID:1312696](#), [PMID:1563005](#), [PMID:1565469](#), [PMID:1845952](#), [PMID:2388294](#), [PMID:2473086](#), [PMID:2985257](#), [PMID:2985258](#), [PMID:2986243](#), [PMID:3335022](#), [PMID:6148444](#), [PMID:6270685](#), [PMID:6713399](#), [PMID:7720728](#), [PMID:8626706](#), [PMID:8806092](#), [PMID:8806103](#), [PMID:10037197](#), [PMID:10709110](#), [PMID:11005564](#), [PMID:11030152](#), [PMID:16157194](#), [PMID:17426248](#), [PMID:19472407](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:20557307](#), [PMID:20615970](#), [PMID:22460905](#), [PMID:22961666](#), [PMID:23716474](#), [PMID:24700732](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25960936](#), [PMID:25984343](#), [PMID:27247353](#), [PMID:27397505](#), [PMID:28766886](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#), [PMID:31978347](#), [PMID:32586373](#), [PMID:34439128](#), [PMID:35839778](#), [PMID:39154123](#)

Comments: Population: Caucasian., Part of: MYC genetic alteration cell panel (ATCC TCP-1035)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: NCI-H82

Synonyms: NCI-H-82, H82, H-82, NCI H82, NCIH82, H82sclc

Cross References: BTO:BTO_0003026, CLO:CLO_0008118, EFO:EFO_0002306, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-175, BioGRID_ORCS_Cell_line:808, BioSample:SAMN03471034, BioSample:SAMN10987912, cancercellines:CVCL_1591, Cell_Model_Passport:SIDM01131, ChEMBL-Cells:ChEMBL3308882, ChEMBL-Targets:ChEMBL2366077, CLS:300442, Cosmic:688031, Cosmic:755461, Cosmic:801351, Cosmic:801611, Cosmic:844546, Cosmic:844818, Cosmic:850430, Cosmic:876166, Cosmic:877198, Cosmic:877352, Cosmic:897520, Cosmic:918011, Cosmic:929978, Cosmic:980927, Cosmic:1006523, Cosmic:1021850, Cosmic:1032393, Cosmic:1152462, Cosmic:1219097, Cosmic:1239935, Cosmic:1891902, Cosmic:1995593, Cosmic:1998280, Cosmic:2125201, Cosmic:2668274, Cosmic:2668342, Cosmic-CLP:688031, DepMap:ACH-000355, DSMZ:ACC-556, DSMZCellDive:ACC-556, EGA:EGAS00001000610, EGA:EGAS00001000978, FANTOM5_SSTAR:10842-111E5, GDSC:688031, GEO:GSM169450, GEO:GSM170730, GEO:GSM170731, GEO:GSM171886, GEO:GSM171887, GEO:GSM380507, GEO:GSM380516, GEO:GSM482517, GEO:GSM536336, GEO:GSM784220, GEO:GSM794270, GEO:GSM827490, GEO:GSM844660, GEO:GSM845551, GEO:GSM887447, GEO:GSM888527, GEO:GSM1374764, GEO:GSM1670266, GEO:GSM1887960, GEO:GSM1887979, IARC_TP53:440, IARC_TP53:21402, IGRhCellID:NCIH82, KCLB:30175, LiGeA:CCLE_485, LINCS_LDP:LCL-1862, NCI-DTP:NCI-H82, PharmacDB:NCIH82_1139_2019, PRIDE:PXD011896, PRIDE:PXD030304, Progenetix:CVCL_1591, PubChem_Cell_line:CVCL_1591, Wikidata:Q54908125

ID: CVCL_1591

Record Creation Time: 20220427T220840+0000

Record Last Update: 20260829T234735+0000

Ratings and Alerts

No rating or validation information has been found for NCI-H82.

No alerts have been found for NCI-H82.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 40 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. Cell reports, 45(7), 117699.

Balke-Want H, et al. (2026) c-JUN enhances CRISPR knockin anti-B7-H3 CAR T cell function in small cell lung cancer and thoracic SMARCA4-deficient undifferentiated tumors. *Cell reports. Medicine*, 7(1), 102549.

Ahmad T, et al. (2026) KDM7B-mediated demethylation of RNF113A regulates small cell lung cancer sensitivity to alkylation damage. *bioRxiv : the preprint server for biology*.

Campisi M, et al. (2026) Vascular STING activation facilitates NK cell anti-tumor immunity in small cell lung cancer. *Cancer cell*, 44(4), 858.

Wang W, et al. (2025) Engineering affinity-matured variants of an anti-polysialic acid monoclonal antibody with superior cytotoxicity-mediating potency. *Cell chemical biology*, 32(8), 1042.

Iñáñez A, et al. (2025) The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer. *International journal of molecular sciences*, 26(3).

Chatterjee D, et al. (2025) KSR1 Mediates Small Cell Lung Carcinoma Tumor Initiation and Cisplatin Resistance. *Molecular cancer research : MCR*, 23(6), 553.

Fnu T, et al. (2025) Sympathetic Neurons Promote Small Cell Lung Cancer through the α -2-Adrenergic Receptor. *Cancer discovery*, 15(3), 616.

Hong D, et al. (2025) Loss of NOTCH2 creates a TRIM28-dependent vulnerability in small cell lung cancer. *Developmental cell*.

De Rosa C, et al. (2025) DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer. *iScience*, 28(3), 111943.

Li C, et al. (2025) Preclinical Evaluation of DB-1419, a Novel Bifunctional and Bispecific Anti-B7-H3 $\times$ PD-L1 Antibody-Drug Conjugate. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(16), 3581.

Lowe E, et al. (2025) Preclinical characterization of novel multi-client inhibitors of Sec61 with broad antitumor activity. *The Journal of pharmacology and experimental therapeutics*, 392(8), 103634.

Giudice AM, et al. (2025) D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(24), 5276.

Martin-Vega A, et al. (2024) ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers. *Molecular cancer therapeutics*, 23(12), 1789.

Chakraborty S, et al. (2024) Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. *Cell reports. Medicine*, 5(12), 101852.

Duplaquet L, et al. (2024) Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer. *Cancer cell*, 42(8), 1352.

Liu S, et al. (2024) UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas. *Cell reports. Medicine*, 5(2), 101381.

Ng J, et al. (2024) Molecular and Pathologic Characterization of YAP1-Expressing Small Cell Lung Cancer Cell Lines Leads to Reclassification as SMARCA4-Deficient Malignancies. *Clinical cancer research : an official journal of the American Association for Cancer Research*, OF1.

Zhu Q, et al. (2024) Cisplatin resistance-related transcriptome and methylome integration identifies PCDHB4 as a novel prognostic biomarker in small cell lung cancer. *iScience*, 27(8), 110413.

Liu S, et al. (2024) Protocol for establishing spontaneous metastasis in mice using a subcutaneous tumor model. *STAR protocols*, 5(3), 103239.